Dr Cheney Drew

2022

• Oliver, C. et al. 2022. A systematic review on adherence to continuous positive airway pressure (CPAP) treatment for obstructive sleep apnoea (OSA) in individuals with mild cognitive impairment and Alzheimer's disease dementia. Sleep Medicine 100, pp. S239. (10.1016/j.sleep.2022.05.641)
• Quinn, L. et al. 2022. Physical activity and exercise outcomes in Huntington's disease (PACE-HD): results of a 12-month trial-within-cohort feasibility study of a physical activity intervention in people with Huntington's disease. Parkinsonism & Related Disorders 101, pp. 75-89. (10.1016/j.parkreldis.2022.06.013)
• Morgan-Jones, P. et al. 2022. Monitoring and managing lifestyle behaviours using wearable activity trackers: a mixed methods study of views from the Huntington's disease community. JMIR Formative Research 6(6), article number: e36870. (10.2196/36870)
• Rosser, A. E. et al. 2022. Translating cell therapies for neurodegenerative diseases: Huntington's disease as a model disorder. Brain 145(5), pp. 1584-1597. (10.1093/brain/awac086)

2021

• Woodgate, S. et al. 2021. Objectively characterizing Huntington’s disease using a novel upper limb dexterity test. Journal of Neurology 268, pp. 2550-2559. (10.1007/s00415-020-10375-8)
• Drew, C. et al. 2021. Protocol for an open label, phase I trial within a cohort of fetal cell transplants in people with Huntington’s disease. Brain Communications 3(1), article number: fcaa230. (10.1093/braincomms/fcaa230)

2020

• Sanders, J. et al. 2020. Pregnancy and weight monitoring: a feasibility study of weightcharts and midwife support. Maternal and Child Nutrition 16(4), article number: e12996. (10.1111/mcn.12996)
• Yhnell, E. et al. 2020. A randomised feasibility study of computerised cognitive training as a therapeutic intervention for people with Huntington's disease (CogTrainHD). Pilot and Feasibility Studies 6, article number: 88. (10.1186/s40814-020-00623-z)

2019

• Drew, C. J. G. et al. 2019. Physical activity and exercise outcomes in Huntington Disease (PACE-HD): Protocol for a 12-Month trial within cohort evaluation of a physical activity intervention in people with Huntington Disease. Physical Therapy 99(9), pp. 1201-1210. (10.1093/ptj/pzz075)
• Drew, C. J. G. et al. 2019. A protocol for a randomised controlled, double-blind feasibility trial investigating fluoxetine treatment in improving memory and learning impairments in patients with mesial temporal lobe epilepsy: Fluoxetine, Learning and Memory in Epilepsy (FLAME trial). Pilot and Feasibility Studies 5(1), article number: 87. (10.1186/s40814-019-0474-x)
• Morgan-Trimmer, S. et al. 2019. The acceptability of fluoride varnish and fissure sealant treatments in children aged 6-9 delivered in a school setting. Community Dental Health 36(1), pp. 33-38. (10.1922/CDH_4263Morgan-Trimmer06)

2017

• Chestnutt, I. G. et al. 2017. Fissure seal or fluoride varnish? A randomised trial of their relative effectiveness. Journal of Dental Research 96(7), pp. 754-761. (10.1177/0022034517702094)
• Busse, M. et al. 2017. Physical activity self-management and coaching compared to social interaction in Huntington’s disease: Results from the ENGAGE-HD randomized, controlled, pilot feasibility trial. Physical Therapy 97(6), pp. 625-639. (10.1093/ptj/pzx031)
• Chestnutt, I. G. et al. 2017. Seal or Varnish? A randomised controlled trial to determine the relative cost and effectiveness of pit and fissure sealant and fluoride varnish in preventing dental decay. Health Technology Assessment 21(21), pp. 1-256. (10.3310/hta21210)

2016

• Drew, C. et al. 2016. Integrating technology into complex intervention trial processes: a case study. Trials 17(1), article number: 551. (10.1186/s13063-016-1674-9)
• Jones, C. et al. 2016. The societal cost of Huntington’s disease: are we underestimating the burden?. European Journal of Neurology 23(10), pp. 1588-1590. (10.1111/ene.13107)
• Randell, E. et al. 2016. The use of everolimus in the treatment of neurocognitive problems in tuberous sclerosis (TRON): study protocol for a randomised controlled trial. Trials 17, article number: 398. (10.1186/s13063-016-1446-6)
• Fry, A. E. et al. 2016. Pathogenic copy number variants and SCN1A mutations in patients with intellectual disability and childhood-onset epilepsy. BMC Medical Genetics 17, pp. -., article number: 34. (10.1186/s12881-016-0294-2)
• Quinn, L. et al. 2016. Development and delivery of a physical activity intervention for people with Huntington Disease. Journal of Neurologic Physical Therapy 40(2), pp. 71-80. (10.1097/NPT.0000000000000119)

2015

• Thomas, R. H., Drew, C., Wood, S. E., Hammond, C. L., Chung, S. K. and Rees, M. I. 2015. Ethnicity can predict GLRA1 genotypes in hyperekplexia. Journal of Neurology, Neurosurgery & Psychiatry 86(3), pp. 341-343. (10.1136/jnnp-2014-307903)

2012

• Thompson, R., Drew, C. and Thomas, R. H. 2012. Next generation sequencing in the clinical domain: clinical advantages, practical, and ethical challenges. Advances in Protein Chemistry and Structural Biology 89, pp. 27-63. (10.1016/B978-0-12-394287-6.00002-1)